Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the
buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal
system (5 mg) and oxycodone immediate release in subjects with moderate to severe
osteoarthritis pain currently treated with oral opioids. The double-blind treatment
intervention duration is 12 weeks during which time supplemental analgesic medication
(acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in
addition to study drug.